2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Updates on Pancreatic Cancer: mFOLFIRINOX vs. Gem/nab-P - Is There a Difference in Efficacy? Should We Consider Neoadjuvant FOLFIRINOX for Borderline Resectable Disease?

1,641 views
September 16, 2020
Comments 0
Login to view comments. Click here to Login